Company Overview and News

1
MYOK / MyoKardia, Inc. 424B5 (Prospectus)

2018-05-21 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223526 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell

1
MYOK / MyoKardia, Inc. 8-K (Current Report)

2018-05-21 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Myokardia's (MYOK) CEO Jack Clem on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen and welcome to the MyoKardia First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will follow at that time. [Operator instructions] As a reminder, this conference call is being recorded.

1
MYOK / MyoKardia, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
myok-10q_20180331.htm UNITED STATES

1
MYOK / MyoKardia, Inc. 8-K (Current Report)

2018-05-08 sec.gov
myok-8k_20180331.htm UNITED STATES

 
MYOK / MyoKardia, Inc. / BlackRock Inc. - null (Passive Investment)

2018-05-08 sec.gov
us62857m1053_050318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MYOKARDIA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 62857M105 -------------------------------------------------------- (CUSIP Number) April 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page sh

 
MYOK / MyoKardia, Inc. / BlackRock Inc. - null (Passive Investment)

2018-05-08 sec.gov
us62857m1053_050318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MYOKARDIA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 62857M105 -------------------------------------------------------- (CUSIP Number) April 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page sh

1
MYOK / MyoKardia, Inc. DEF 14A

2018-04-17 sec.gov
myok-def14a_20180612.htm UNITED STATES

1
MYOK / MyoKardia, Inc. DEFINITIVE ADDITIONAL MATERIALS

2018-04-17 sec.gov
Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
MYOK / MyoKardia, Inc. 8-K (Current Report)

2018-04-04 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

1
Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results

2018-04-03 seekingalpha
After a sell-off last week, MediciNova (NASDAQ:MNOV) shares have bounced back sharply in trading today as the company announced that it is terminating a phase 2 study of MN-001 in NASH and NAFLD with hypertriglyceridemia early based on the significant positive results from an interim analysis.

4
Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC

2018-03-10 seekingalpha
Today, we will discuss Immuron (IMRN) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in the U.S.

 
MyoKardia Sees Positive Results in Mid-Stage Heart Trial

2018-03-09 biospace
Shares of MyoKardia spiked in late trading Thursday after the company revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial. This morning shares of MyoKardia Inc. are climbing again, up more than 5 percent following the opening bell.

 
MyoKardia's (MYOK) CEO Tassos Gianakakos on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
Good day, ladies and gentlemen and welcome to the MyoKardia Fourth Quarter 2017 Financial Results Conference Call.

 
MYOK / MyoKardia, Inc. S-3ASR

2018-03-08 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 8, 2018 Registration No. 333-

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 62857M105